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ABSTRACT
Objectives: To assess whether bosentan or no active intervention, in addi-
tion to palliative care, is the more cost-effective ﬁrst-line treatment option
for patients with idiopathic pulmonary arterial hypertension (iPAH) or
PAH associated with connective tissue disease (PAH-CTD) of WHO func-
tional classiﬁcation (FC) III in the United Kingdom.
Methods: A cost-utility model simulated the treatment of patients with
PAH of FC III. Patients remained on the selected intervention until death
or clinical deterioration to FC IV, which would trigger initiation of epo-
prostenol treatment. The initial ﬁrst-line treatment choice was assumed to
not affect survival, but to affect the time until clinical deterioration, with
this assumption being relaxed in sensitivity analyses. The distribution of
time to clinical deterioration was estimated from long-term clinical trial
databases of bosentan and from published literature. Utility associated
with FC was taken from published literature. Costs were sourced from
published literature and from specialist PAH centers. The time horizon
was that of patients’ lifetimes, with costs and beneﬁts discounted at 3.5%
per annum.
Results: In the base case, bosentan dominated no active intervention
because of the longer time to clinical deterioration and therefore the
reduced time, per patient, spent in FC IV, which was associated with high
costs of epoprostenol and reduced utility. In sensitivity analyses, bosentan
was estimated to be more cost-effective than no active intervention, pro-
vided that any survival beneﬁt was not greater than 2 years for patients
with iPAH and 1 year for those with PAH-CTD.
Conclusions: Bosentan is likely to be a more cost-effective ﬁrst-line
therapy for patients with PAH FC III in the UK than no active intervention.
Keywords: cost-effectiveness, mathematical modeling, pulmonary arterial
hypertension, simulation.
Introduction
Disease Overview
Pulmonary arterial hypertension (PAH) is a rare but devastating
disease that is characterized by elevated pulmonary vascular
resistance eventually leading to increased right heart pressures,
right heart failure, and untimely death [1,2]. The disease can
either be classiﬁed as idiopathic (iPAH) or associated with other
conditions, such as connective tissue disease (CTD), congenital
heart disease, or human immunodeﬁciency virus. Patients are
classiﬁed according to the degree of functional impairment based
on exercise tolerance, using the New York Heart Association/
World Health Organization (NYHA/WHO) functional classiﬁ-
cation (FC), which ranges from least severe, FC I, to most severe,
FC IV. The prevalence of the more severe classiﬁcation of PAH
(FC III and IV) is estimated to be from 30 to 50 cases per million
[3], which equates to approximately 1800 to 3000 patients with
FC III or FCIV in the United Kingdom.
PAH has a signiﬁcant impact on patients’ quality of life [4,5]
and mortality [6]. Median survival after diagnosis of iPAH in an
untreated population has been estimated at 2.5 years for those in
FC III [6], which is comparable with prognoses in some advanced
cancers [7].
Improving survival, stabilizing disease and improving quality
of life are key aims in any treatment strategy for patients with
PAH. Because there is no cure for PAH, patients will ultimately
deteriorate, resulting in additional treatments, including con-
tinuous intravenous treatment with prostaglandins (PGs), lung
transplantation (in very few cases), or death [8].
Treatment Options
Historically, standard care in the United Kingdom for patients
with PAH FC III was palliative care (diuretics, warfarin, and
calcium antagonists, as required), with the option for continuous
i.v. PGs, typically epoprostenol, once they reached FC IV [9].
Nevertheless, the treatment armoury was extended in 2002 with
the launch of bosentan. Bosentan is an oral dual endothelin
receptor antagonist licensed for the treatment of PAH. Bosentan
competitively blocks both ETA and ETB, and therefore decreases
both pulmonary and systemic vascular resistance, resulting in
increased cardiac output without increasing heart rate [10]. In
the United Kingdom, bosentan (Tracleer Actelion Registration
Ltd., London, UK) is indicated for the treatment of PAH to
improve exercise capacity and symptoms in patients in FCIII. In
addition, improvements have also been shown in patients with
FC II; bosentan is also indicated to reduce the number of new
digital ulcers in patients with systemic sclerosis and ongoing
digital ulcer disease. Since the launch of bosentan, the treatment
armory has been further extended with the introduction of addi-
tional pharmaceutical interventions (sildenaﬁl, sitaxentan, ven-
tavis, and ambrisentan).
Objectives
We aim to assess in the context of England and Wales which of
bosentan or no active intervention, each used in addition to
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palliative care, represents the more cost-effective ﬁrst-line
therapy for FC III patients within the two largest subgroups of
PAH, i.e., patients with iPAH, or PAH related to CTD (PAH-
CTD). Emphasis was placed on using long-term data (with
follow up for up to 3 years) as the basis for the cost-effectiveness
model because these would provide a more robust measure of
disease progression than modeled extrapolations of randomized
controlled trials (RCT) that are typically restricted to a
maximum of 16 weeks and use surrogate end points.
Ideally, sildenaﬁl sitaxentan and ambrisentan should be
modeled as well to determine the most cost-effective ﬁrst-line
treatment from all currently licensed treatment options;
however, necessary data were not available to incorporate these
interventions: For sildenaﬁl published efﬁcacy data for the
licensed dose of 20 mg thrice daily stems from a small sample
RCT (n = 40 in FC III) with a short follow-up period (12 weeks)
[11]; Limited long term data exist for this dose to date. For
sitaxentan and ambrisentan, only 1-year long-term data from
open-label extension studies of RCTs have been published in
peer-reviewed journals to date [12,13]; however, these did not
provide the detailed level of information required to model clini-
cal deterioration as deﬁned here. No data beyond 1 year have
been published.
Intravenous PGs are rarely used in FC III patients because of
the associated expense and the route of administration, which
carries the risk of line infections. Therefore, i.v. PGs have been
included as the treatment provided to those who fail oral treat-
ment by deteriorating to FC IV.
The Efﬁcacy of Bosentan
The efﬁcacy and safety of bosentan has been demonstrated in a
range of studies, including two pivotal, randomized, double-
blind, placebo controlled trials [14,15]. These trials showed sta-
tistically signiﬁcant (P < 0.05) improvements versus placebo at
12 and 16 weeks in the 6-minute walk test (6MWT) [9], a
standardized test that measures the distance a patient can walk
quickly on a ﬂat, hard surface in a period of 6 minutes. Bosentan
was also shown to signiﬁcantly reduce the time to clinical wors-
ening, a composite end point, which included death, lung
transplantation, PAH-related hospitalization, PAH worsening
leading to discontinuation, need for PGs, or atrial septostomy
[15,16].
Longer-term studies have been undertaken, where patients
who completed the pivotal RCTs had the option to continue or
switch to bosentan treatment, with the addition of other treat-
ments where necessary. From these long-term studies, the sur-
vival of patients with iPAH, who began on bosentan treatment in
addition to palliative care, was estimated at 96, 89, 86% at 1, 2,
and 3 years, compared with a predicted survival of 69, 57, 48%,
respectively, for iPAH patients treated with palliative care only
[16]. In the long-term study in iPAH, the majority of patients
remained on bosentan monotherapy (85% and 70% at 1 and 2
years, respectively). For patients with PAH associated with CTD
(a patient cohort with an even poorer prognosis), survival with
bosentan was estimated at 86% and 73% at 1 and 2 years, which
is signiﬁcantly higher than the 55% 1-year survival of untreated
patients [17].
All long-term data to date has been collected within open-
label extension studies. Conducting long-term RCTs in a rare and
life-threatening condition such as PAH poses considerable chal-
lenges because of the difﬁculty in recruitment of adequate
numbers of patients and the ethical issues of carrying out
placebo-controlled studies on a long-term basis in patients with
poor prognoses.
Methods
Description of the Cost-Effectiveness Model
A mathematical model was constructed to simulate the changes
in FC and the time until death of hypothetical FC III patients
with either iPAH or PAH-CTD. The time horizon was that of
patient lifetime. The cost perspective was that of the NHS with
only direct costs considered. Ten thousand patients were simu-
lated and replicated to form two cohorts, one that received
bosentan and palliative care and one that received palliative care
only. There was a possibility of a change in an individual’s FC in
the ﬁrst 12 weeks of treatment, the probability of which was
taken from RCTs of patients with iPAH (Table 1). These were
also assumed applicable to patients with PAH-CTD. Patients
deteriorating to FC IV at 12 weeks were assumed to change
treatments to epoprostenol and palliative care.
For each patient, predicted life expectancy and the “time to
clinical deterioration” (TTCD), a metric that estimates the long-
term progression of PAH to FC IV and which is described later,
were compared. If the life expectancy of the patient was lower
than the TTCD, it was assumed that the patient remained on
their intervention and within their FC at 12 weeks until death. If
the TTCD was lower than the life expectancy, it was assumed
that the patient would remain in their FC at 12 weeks until
TTCD, at which time the patient was assumed to deteriorate to
FC IV and receive epoprostenol and palliative care until death.
For each patient, a discrete event simulation approach was used
where the simulated time moved directly to the time of the next
scheduled event (either TTCD or death). This approach was used
because it was more computationally efﬁcient and removed the
need for establishing arbitrary durations for the time cycles
required by Markov models.
In the base case, the life expectancy of a patient was assumed
to be independent of the initial treatment prescribed; assuming
both that clinicians would be vigilant in observing deterioration
and that there would be some stabilization of disease once epo-
prostenol is prescribed. The outcome measure that would thus
vary between interventions would be the proportion of time
spent by the patient in the most severe disease state, with the least
efﬁcacious intervention (palliative care alone) being associated
with a longer duration in FC IV. The proportion of time a patient
resides in FC IV affects cost-effectiveness because the utility
associated with being in this class is lower than in FC III [5], and
because the relatively expensive epoprostenol treatment, the
cheapest i.v. PG at the time of the study (Table 2) would be
initiated. The assumption of constant and treatment-independent
Table 1 The number of patients, initially in functional class III, in each functional class following 12 weeks of treatment
Intervention n
Functional class after 12 weeks of treatment
SourceI II III IV
Bosentan 139 2 (1%) 52 (37%) 83 (60%) 2 (1%) Channick et al. [14] and Rubin et al. [15]
No active intervention 65 0 (0%) 19 (29%) 42 (65%) 4 (6%) Rubin et al. [15]
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life expectancy may be counter-intuitive because it would seem
reasonable to assume that bosentan provides a survival advan-
tage compared with no active intervention. Nevertheless, we
conservatively assumed no impact on survival, because there are
no data on the incremental survival beneﬁt by bosentan, and then
tested this assumption within sensitivity analyses.
Beyond the TTCD for bosentan, all patients, regardless of
initial therapy would either be in FC IV and be receiving epopros-
tenol and palliative care, or would be dead. In either circumstance,
the costs and quality-adjusted life-years (QALYs) accrued would
be identical regardless of the initial treatment. This allowed the
lower of the TTCD for bosentan or life expectancy to be used as
the time horizon for each patient, thereby reducing computational
time of the model. Figure 1 provides a schematic of the care
pathway for a patient with iPAH and an average TTCD, which is
assumed shorter than the patient’s life expectancy.
The model calculates the costs and QALYs associated with
each treatment strategy with analyses undertaken separately for
iPAH patients and for those with PAH-CTD. Both beneﬁts and
costs have been discounted at a rate of 3.5% per annum as
recommended by the National Institute for Health and Clinical
Excellence [18].
Primary Outcome Measure
Although the primary end point of RCTs has been 6MWT, which
measures symptom severity and physical functioning, we have
not modelled on this parameter. Although the baseline value of
the 6MWT has been shown to be predictive of survival, the
change in the distance from pre- to posttreatment has consis-
tently not been found to be of prognostic value [13,19–23; Sitbon
O, Channick R, McLaughlin W, unpubl, data]. The CE model
has instead used “time to clinical deterioration” (TTCD), an
outcome parameter reﬂecting progression of disease over longer
time periods than seen in the RCT. For bosentan, the data for
TTCD was collated from the combined data set of the two
bosentan pivotal RCTs [11,12], the long-term follow-up of these
studies [Actelion, unpubl. data], and a database associated with
the article by Williams et al. [24], a longitudinal study recruiting
patients with CTD-PAH. These sources, which provide data for
periods of up to 3 years, are hereafter referred to as the full
bosentan dataset. The TTCD was deﬁned as the time at which a
patient discontinued bosentan monotherapy, either through the
addition (or substitution) of another intervention or through
death. In the full bosentan database, 46 of 169 patients with
iPAH had a TTCD, with corresponding values for PAH-CTD
being 30 and 66, highlighting the poorer prognosis of PAH-CTD
patients. TTCD was used within the model as a proxy for the
time at which the patient would deteriorate to FCIV and receive
epoprostenol and palliative care. It should be noted therefore
that TTCD is not equivalent to the “time to clinical worsening”
endpoint from the randomized controlled trials; TTCD should be
a more robust measure, reﬂecting clinically and economically
relevant outcomes.
Estimating the TTCD
Kaplan–Meier analysis was conducted in STATA (STATA Corpo-
ration, College Station, TX) using all data from the bosentan full
data set in order that informative data were not excluded. PAH
type and FC were used as covariates in the model to avoid bias in
estimating the distribution for patients with IPAH of FC III and
CTD-PAH of FC III. Patients who were alive and remained on
bosentan and palliative care were censored. The best ﬁtting dis-
tribution of TTCD for bosentan was a Weibull model with a
shape parameter of 1.11 (95% conﬁdence interval 0.93–1.33),
with the scale parameters calculated separately for patients with
iPAH and PAH-CTD. The mean duration of TTCD for patients
in FC III treated with bosentan was 6.54 years for patients with
iPAH and 2.46 years for patients with PAH-CTD.
The distribution of TTCD for patients with iPAH, who
received palliative care alone, was estimated from the median
time to death reported by D’Alonzo et al. [6]. Epoprostenol
treatment was not readily available to patients in the D’Alonzo
study but is now regularly used in severe cases; we have therefore
Table 2 The annual costs of bosentan, epoprostenol, and supportive
therapy treatment
Treatment
Acquisition
cost*
Home
delivery
costs
Additional
palliative
care
costs
Total
cost
Bosentan £20,102 £1,608 £1,773 £23,483
Epoprostenol £47,508 £3,801 £9,036 £60,344
No active intervention £– £– £1,303 £1,303
*http://www.bnf.org [Accessed December 31, 2007].
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Figure 1 A schematic of the care pathway for an average patient with iPAH of FC III. FC, functional classiﬁcation; iPAH, idiopathic pulmonary arterial hypertension;
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assumed that epoprostenol treatment would now be initiated
(with the patient progressing to FC IV) at the time of death
estimated by D’Alonzo et al. [6]. If epoprostenol would be initi-
ated before this time to prevent mortality, then this assumption
will underestimate the costs of ﬁrst-line palliative care alone. It
was assumed that the TTCD for iPAH initially treated with
palliative care alone would be a Weibull distribution with a shape
equal to that for bosentan treatment and the scale calculated so
that the median time to death was equal to the 2.5 years reported
by D’Alonzo et al. [6]. This resulted in a TTCD for patients with
iPAH treated with palliative care alone of 3.51 years. No data
were found on the survival of patients with PAH related to CTD
treated with palliative care alone. It was assumed that the ratio
in survival times between iPAH and PAH-CTD calculated for
patients treated with bosentan (2.46/6.54) was applicable for
patients treated with palliative care alone, resulting in a predicted
TTCD for patients with PAH-CTD treated with palliative care
alone of 1.32 years.
TTCDs were sampled independently for bosentan with pal-
liative care and for palliative care alone. It was deemed implau-
sible that a patient receiving palliative care alone would have a
TTCD that was larger than that of a corresponding patient
receiving bosentan and palliative care. Where the estimated
TTCD values for an individual patient did not ﬁt this constraint,
the TTCD associated with palliative care treatment was reduced
to that of bosentan plus palliative care.
Patient Characteristics
The distribution of patient age for those with iPAH or PAH
related to CTD was estimated from the full bosentan dataset
using STATFIT (Geer Mountain Software Corp., Rolla, MO),
assuming no correlation between age at presentation and FC.
This information was used in conjunction with UK life tables to
determine the life expectancy [25], assuming that the average of
male and female values was applicable. The distribution of age
(in years) for patients with iPAH was a triangular distribution
with a minimum value of 10.4, a maximum value of 82.4 and a
most likely value of 50.9. The age of patients with PAH-CTD
was represented as a beta distribution (alpha = 2.39, beta = 1.88)
scaled to ﬁt between 26 and 80 years.
Utility associated with functional class. The utility associated
with each FC has been taken from Keogh and colleagues [5], who
recorded SF-36 data for patients receiving bosentan treatment
for a period of between 3 and 6 months. The utility values
(0.73, 0.67, 0.60, and 0.52 for patients in FC I, II, III and IV,
respectively) were assumed to apply to both patients with iPAH
and those with PAH related to CTD. No differentiation in utility
was made between treatments.
Costs used within the model. The acquisition costs, in December
2007, of bosentan (Tracleer 62.5 mg and 125 mg twice daily),
epoprostenol (Flolan [Glaxo Wellcome UK Ltd., Uxbridge,
Middlesex, UK] 1.5 mg, diluted to 20 ml per day) and palliative
care are given in Table 2. We have included home delivery costs
for bosentan and epoprostenol, which, on the advice of a PAH
specialist center, were assumed to be 8% of drug acquisition
costs. The costs of palliative care have been estimated from data
provided by two specialist PAH centers. These specialist centers
also provided data on the one-off costs of initiating therapy,
which were estimated at £1547 for both bosentan and palliative
care and £11,016 for an i.v. PG. All costs refer to the 2006 to
2007 ﬁnancial year.
Calculation of Results
Deterministic analyses were undertaken using the midpoint value
for each parameter. Probabilistic sensitivity analyses (PSA) were
conducted varying the shape and scale of the TTCD for each
treatment, the ratio of TTCD between patients with iPAH, and
those with PAH-CTD, and the utility associated with each FC.
The distributions of values used for parameters in the PSA are
given in Table 3. Further sensitivity analyses relaxed the assump-
tion that all patients have the same survival duration irrespective
of ﬁrst-line treatment. This was undertaken to examine the
effects on the cost-effectiveness ratio if it were assumed that
patients who received palliative care only died more quickly than
those who started with bosentan. Sensitivity analyses on survival
beneﬁt used the midpoint value for each parameter.
Results
The results were similar in both the deterministic and probabi-
listic analyses. The discounted costs and QALYs for each treat-
ment strategy produced by the PSA analyses are provided in
Table 4. In all of the 1000 parameter conﬁgurations, bosentan
with palliative care as a ﬁrst-line treatment provided more
QALYs and was cost-saving compared with palliative care only.
This is reﬂective of the faster progression of patients receiving
palliative care alone to FC IV, which is associated with the
initiation of the relatively expensive epoprostenol and a reduc-
tion in utility. The results from the analyses that relaxed the
assumption that life expectancy was independent of initial
Table 3 The distribution of parameters used in the probabilistic sensitivity analyses
Midpoint value
Range
Source/notesLower 95% CI Upper 95% CI
Shape for Weibull distribution 1.113 0.931 1.330 Calculated from the full bosentan data.Assumed
applicable to palliative care.
Scale of Weibull distribution for FC III patients Treatment speciﬁc Calculated using multivariate normal
techniques based on the sampled
shape of the distribution
The full bosentan database and D’Alonzo et al. [6]
Ratio of survival for patients with PAH
associated with CTD compared
with patients with iPAH
0.376 Calculated from the full bosentan data.Assumed
applicable to palliative care.
Utility FC I 0.73 0.64 0.82 Keogh et al. [5].Assumed applicable for all
interventions.To maintain consistency between
the classes we sampled the same percentile
from each of the four distributions.
Utility FC II 0.67 0.57 0.77
Utility FC III 0.60 0.50 0.70
Utility FC IV 0.52 0.43 0.61
Note that these references are [6] (D’Alonzo) and [5] (Keogh).
CI, conﬁdence interval; CTD, connective tissue disease; FC, functional classiﬁcation; iPAH, idiopathic pulmonary arterial hypertension.
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treatment are given in Figure 2. The cost per QALY of bosentan
compared with palliative care alone became £30,000 (a potential
cost-effectiveness threshold used in the United Kingdom) [19] or
more when the survival beneﬁt of bosentan treatment increased
beyond 2 years for patients with iPAH, and when the survival
beneﬁt of bosentan approached 1 year for patients with
PAH-CTD.
Discussion
Our results show that added to palliative care, bosentan is a more
cost-effective ﬁrst-line therapy for FC III patients with iPAH or
PAH-CTD than no active intervention. There are insufﬁcient data
to analyze further etiology subgroups, but it is likely that these
results can be extrapolated to other types of PAH FC III.
Our results are not dissimilar to previously published models.
Wlodarczyk et al. concluded that bosentan is a potentially cost-
effective in an Australian context [26], while Highland et al.
concluded that bosentan was more cost-effective than either epo-
prostenol or treprostinol [27]. Our analysis, however, has the
strength of a longer and more populated data set, from which
TTCD were predicted.
Our methodology has some limitations: The base-case
assumed that survival was independent of initial treatment,
which is likely to be incorrect, because bosentan has been shown
to provide a survival advantage of currently undetermined length
[17,18]. Similar life expectancies would rely on clinicians care-
fully monitoring patients on palliative care alone and providing
prompt epoprostenol treatment as the patient deteriorates to FC
IV. Sensitivity analyses have shown that any survival advantage
of bosentan has a marked effect on the cost-effectiveness, which
reﬂects the frequent issue that it can be more cost-effective to let
patients die rather than to use relatively costly treatments. Data
on the additional survival associated with initial bosentan treat-
ment rather than no active intervention are not available and will
be difﬁcult to generate, because long-term comparative studies
using placebo are ethically not justiﬁable.
Our results are dependent on i.v. PGs being a treatment
option for patients in FC IV. Were this withdrawn because of
high acquisition costs, then bosentan would likely not be cost-
effective compared with no active intervention. We have not
explicitly modeled this scenario assuming that it would be
unethical to remove a widely used last resort treatment from
the physicians’ armory. We have excluded the possibility that
patients, who initiate epoprostenol in FC IV, could improve to
FC III, and have also not modeled the disutility associated with
receiving continuous intracardiac infusion. Nevertheless, because
these effects are independent of the initial treatment (bosentan or
no active intervention) and may counterbalance themselves, these
omissions are unlikely to bias the results.
It was assumed that the rate of hospitalization was inde-
pendent of treatment or functional class, allowing these costs to
be excluded. This is likely to be favorable to palliative care
because patients deteriorate to FC IV most quickly on this
treatment, which is likely to be associated with a greater
number of hospitalizations.
Not all treatments for PAH have been evaluated as the data
needed to determine TTCD at licensed doses for interventions
other than bosentan, and no active intervention were not avail-
able to the authors. Thus, only conclusions regarding the cost-
effectiveness of bosentan compared with no active treatment
can be made until comparable long-term data on TTCD
become available for the licensed comparators, allowing for
an indirect comparison of treatment options after appro-
priately controlling for differences in study designs and study
populations.
Because of the absence of clinical data, the scenarios modeled
do not consider combination therapy options, such as initiating
two active interventions while in FC III or using bosentan and
epoprostenol concurrently once a patient has deteriorated to FC
Table 4 Cost per QALY results, per patient, from the probabilistic sensitivity analyses
Type of PAH First-line treatment
Discounted
costs
(£000)
Discounted
QALYs
Cost per QALY compared
with palliative care (£000)
Idiopathic Bosentan 134 3.32 Dominating
Palliative care 203 2.95 n/a
Related to CTD Bosentan 62 1.36 Dominating
Palliative care 94 1.21 n/a
Dominating denotes producing more QALYs at a lower cost.
CTD, connective tissue disease; n/a, not applicable; PAH, pulmonary arterial hypertension; QALY, quality-adjusted life-year.
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IV. Once data become available, the relative cost-effectiveness of
such strategies can be assessed.
Conclusion
Compared with no active intervention, bosentan is a potential
cost-effective ﬁrst-line treatment for UK patients with iPAH or
PAH-CTD within FC III. It is estimated to be more cost-effective
than palliative care, followed by epoprostenol, providing that the
survival beneﬁt of bosentan followed by epoprostenol is not
greater than 2 years for patients with iPAH and 1 year for
patients with PAH-CTD.
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